Description of Invention:
Peptides with laminin activity, including YIGSR, are claimed. These peptides block angiogenesis, alter the formation of capillary structures by endothelial cells, prevent the formation of excess blood vessels in tissue and inhibit in vivo tumor cell colonization of tissues. These peptides can be used, among other things, to inhibit metastasis.
Potential Area of Application:
cancer therapeutic
research reagent
Main Advantage of Invention:
encourage cell adhesion
inhibits metastasis and angiogenesis
Inventors:
Y Yamada (NIDCR) JO Graf (NIDCR) Y Iwamoto (NIDCR) F Robey (NIDCR) HK Kleinman (NIDCR) M Sasaki (NIDCR) GR Martin (NIDCR)
Patent Status:
DHHS Reference No. E-521-1986/3 --
U.S. Patent 5,092,885 issued 03 Mar 1992
Related Technologies: DHHS Reference No. E-246-1988/0 --
U.S. Pat. No. 5,211,657 issued 18 May 1993, entitled "Laminin A Chain Deduced Amino Acid Sequence, Expression Vectors and Active Synthetic Peptides"
Relevant Publication:
Y Iwamoto, M Nomizu, Y Yamada, Y Ito, K Tanaka, Y Sugioka. Inhibition of angiogenesis, tumor growth and experimental metastasis of human fibrosarcoma cell HT 1080 by a multimeric form of the laminin sequence Tyr-Ile-Ser-Arg (Y-I-G-S-R). B.J. Cancer 73:589, 1996.
WH Kim, HW Schnaper, M Nomizu, Y Yamada, HK Kleinman. Apoptosis in human fibrosarcoma cells is induced by a multimeric synthetic YIGSR-containing polypeptide from laminin. Cancer Res 54:5005, 1994.
K Yamamura, MC Kibbey, SH Jun, HK Kleinman. Effect of Matrigel and laminin peptide YIGSR on tumor growth and metastasis. Semin Cancer Biol 1993 Aug; 4(4):259-65.
M Nomizu, K Yamamura, HK Kleinman, Y Yamada. Multimeric forms of Tyr-Ile-Gly-Ser-Arg (YIGSR) peptide enhance the inhibition of tumor growth and metastasis. Cancer Res 1993 Aug 1;53(15):3459-61.
J Graf, Y Iwamoto, M Sasaki, GR Martin, HK Kleinman, FA Robey, Y Yamada. Identification of an amino acid sequence in laminin mediating cell attachment, chemotaxis, and receptor binding. Cell 1987 Mar 27;48(6):989-9.
Licensing Status: Available for exclusive or non-exclusive licensing
Portfolios: Cancer
Cancer -Therapeutics
For Additional Information Please Contact: Jasbir (Jesse) S. Kindra J.D.
NIH Office of Technology Transfer
6011 Executive Blvd, Suite 325
Rockville, MD 20852-3804
Phone: (301) 435-5559
Email: kindraj@mail.nih.gov
Fax: (301) 402-0220
